Login
$STAA
$26.01 -$0.38 (1.44%) Live

Company Executives

Officer Age In this role Joined 2025 pay Source
Warren Foust
President and CEO
Title from the Form 4 dated Aug 14, 2026
50 Not stated 2023 $4,440,664
Deborah Andrews
Chief Financial Officer & EVP
Title from the Form 4 dated Aug 14, 2026
68 Not stated 2025 $2,582,411
Magda Michna
Chief Development Officer
50 Since 2025
1 year
2023 $2,695,752
David Bailey
Chief Commercial Officer
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
1.1 years
from year joined
CEO also chairs the board
No
Neal C. Bradsher
Director Age On board Independent Other public boards 2025 pay Source
Neal C. Bradsher
60 2026
this year
Independent Lineage Cell Therapeutics, Inc. Not stated
Arthur C. Butcher
55 2024
2 years
Independent Acotec Scientific Holdings Ltd. $243,394
Wei Jiang
62 2024
2 years
Not independent Waters Corporation $1,536,047
Richard T. LeBuhn
61 2026
this year
Independent None stated Not stated
Louis E. Silverman
67 2025
1 year
Independent Insight Molecular Diagnostics Inc. $254,787
Christopher M. Wang
55 2026
this year
Independent None stated Not stated
Lilian Y. Zhou
43 2023
3 years
Independent None stated $448,571

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed May 4, 2026
Wei Jiang
one of our directors
$1,275,000
fiscal 2025

Consulting agreement under which Mr. Jiang serves as special strategic advisor to the Asia Pacific business, compensated with RSUs

Wei Jiang
one of our directors
Amount not stated

Continued provision of standard non-employee director compensation to Mr. Jiang while serving as advisor

Broadwood
holder of more than 5% of the Company's outstanding stock
Amount not stated
January 14, 2026

Cooperation Agreement with Broadwood, including board size increase, director resignations and appointments, and nomination of New Directors

With the Company Open in proxy
Broadwood
holder of more than 5% of the Company's outstanding stock
$5,036,000

Reimbursement of fees and expenses paid to Broadwood under the Cooperation Agreement

With the Company Open in proxy
Yunqi Capital
holder of more than 5% of the Company's outstanding stock
$962,000

Reimbursement of fees and expenses paid to Yunqi Capital under the Cooperation Agreement

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support